FIGURE 1.

Anlotinib resensitized gefitinib‐resistant PC9/GR cells to gefitinib. (a–c) Parental lung adenocarcinoma PC9 cells and gefitinib‐resistant PC9/GR cells were treated with indicated concentrations of gefitinib (a), anlotinib (b), or gefitinib plus anlotinib (c) for 72 h. Cell viability was measured with a CCK8 assay. (d) The combination index (CI) of gefitinib plus anlotinib was calculated using CompuSyn software. (e) Half maximal inhibitory concentration (IC50) and CI values of gefitinib alone or combined with anlotinib in PC9/GR cells